Vol. 84 Wednesday, No. 132 July 10, 2019 Pages 32839–32974

Total Page:16

File Type:pdf, Size:1020Kb

Vol. 84 Wednesday, No. 132 July 10, 2019 Pages 32839–32974 Vol. 84 Wednesday, No. 132 July 10, 2019 Pages 32839–32974 OFFICE OF THE FEDERAL REGISTER VerDate Sep 11 2014 19:03 Jul 09, 2019 Jkt 247001 PO 00000 Frm 00001 Fmt 4710 Sfmt 4710 E:\FR\FM\10JYWS.LOC 10JYWS jspears on DSK30JT082PROD with FR-WS II Federal Register / Vol. 84, No. 132 / Wednesday, July 10, 2019 The FEDERAL REGISTER (ISSN 0097–6326) is published daily, SUBSCRIPTIONS AND COPIES Monday through Friday, except official holidays, by the Office PUBLIC of the Federal Register, National Archives and Records Administration, under the Federal Register Act (44 U.S.C. Ch. 15) Subscriptions: and the regulations of the Administrative Committee of the Federal Paper or fiche 202–512–1800 Register (1 CFR Ch. I). The Superintendent of Documents, U.S. Assistance with public subscriptions 202–512–1806 Government Publishing Office, is the exclusive distributor of the official edition. Periodicals postage is paid at Washington, DC. General online information 202–512–1530; 1–888–293–6498 Single copies/back copies: The FEDERAL REGISTER provides a uniform system for making available to the public regulations and legal notices issued by Paper or fiche 202–512–1800 Federal agencies. These include Presidential proclamations and Assistance with public single copies 1–866–512–1800 Executive Orders, Federal agency documents having general (Toll-Free) applicability and legal effect, documents required to be published FEDERAL AGENCIES by act of Congress, and other Federal agency documents of public Subscriptions: interest. Assistance with Federal agency subscriptions: Documents are on file for public inspection in the Office of the Federal Register the day before they are published, unless the Email [email protected] issuing agency requests earlier filing. For a list of documents Phone 202–741–6000 currently on file for public inspection, see www.federalregister.gov. The seal of the National Archives and Records Administration The Federal Register Printing Savings Act of 2017 (Pub. L. 115- authenticates the Federal Register as the official serial publication 120) placed restrictions on distribution of official printed copies established under the Federal Register Act. Under 44 U.S.C. 1507, of the daily Federal Register to members of Congress and Federal the contents of the Federal Register shall be judicially noticed. offices. Under this Act, the Director of the Government Publishing The Federal Register is published in paper and on 24x microfiche. Office may not provide printed copies of the daily Federal Register It is also available online at no charge at www.govinfo.gov, a unless a Member or other Federal office requests a specific issue service of the U.S. Government Publishing Office. or a subscription to the print edition. For more information on how to subscribe use the following website link: https:// The online edition of the Federal Register is issued under the www.gpo.gov/frsubs. authority of the Administrative Committee of the Federal Register as the official legal equivalent of the paper and microfiche editions (44 U.S.C. 4101 and 1 CFR 5.10). It is updated by 6:00 a.m. each day the Federal Register is published and includes both text and graphics from Volume 1, 1 (March 14, 1936) forward. For more information, contact the GPO Customer Contact Center, U.S. Government Publishing Office. Phone 202-512-1800 or 866-512- 1800 (toll free). E-mail, gpocusthelp.com. The annual subscription price for the Federal Register paper edition is $860 plus postage, or $929, for a combined Federal Register, Federal Register Index and List of CFR Sections Affected (LSA) subscription; the microfiche edition of the Federal Register including the Federal Register Index and LSA is $330, plus postage. Six month subscriptions are available for one-half the annual rate. The prevailing postal rates will be applied to orders according to the delivery method requested. The price of a single copy of the daily Federal Register, including postage, is based on the number of pages: $11 for an issue containing less than 200 pages; $22 for an issue containing 200 to 400 pages; and $33 for an issue containing more than 400 pages. Single issues of the microfiche edition may be purchased for $3 per copy, including postage. Remit check or money order, made payable to the Superintendent of Documents, or charge to your GPO Deposit Account, VISA, MasterCard, American Express, or Discover. Mail to: U.S. Government Publishing Office—New Orders, P.O. Box 979050, St. Louis, MO 63197-9000; or call toll free 1-866-512-1800, DC area 202-512-1800; or go to the U.S. Government Online Bookstore site, see bookstore.gpo.gov. There are no restrictions on the republication of material appearing in the Federal Register. How To Cite This Publication: Use the volume number and the page number. Example: 84 FR 12345. Postmaster: Send address changes to the Superintendent of Documents, Federal Register, U.S. Government Publishing Office, Washington, DC 20402, along with the entire mailing label from the last issue received. VerDate Sep 11 2014 19:03 Jul 09, 2019 Jkt 247001 PO 00000 Frm 00002 Fmt 4710 Sfmt 4710 E:\FR\FM\10JYWS.LOC 10JYWS jspears on DSK30JT082PROD with FR-WS III Contents Federal Register Vol. 84, No. 132 Wednesday, July 10, 2019 Agriculture Department Energy Department See Farm Service Agency See Federal Energy Regulatory Commission See Food and Nutrition Service See Forest Service Environmental Protection Agency Antitrust Division RULES NOTICES Designation of Areas for Air Quality Planning Purposes: Changes Under the National Cooperative Research and California; Coachella Valley 8-Hour Ozone Nonattainment Production Act: Area; Reclassification to Extreme, 32841–32845 Cooperative Research Group on HEDGE IV, 32950 PROPOSED RULES Heterogeneous System Architecture Foundation, 32951 Air Quality State Implementation Plans; Approvals and Proposed Final Judgment and Competitive Impact Promulgations: Statement: Georgia; Miscellaneous Revisions, 32851–32852 United States v. Harris Corp. and L3 Technologies, Inc., State Hazardous Waste Management Program: 32951–32961 Texas, 32852–32853 Centers for Disease Control and Prevention Farm Service Agency NOTICES RULES Agency Information Collection Activities; Proposals, Emergency Conservation Program, 32839–32841 Submissions, and Approvals, 32918–32924 Request for Information: Mesothelioma Registry Feasibility, 32917 Federal Energy Regulatory Commission Technical Report: NOTICES The NIOSH Occupational Exposure Banding Process for Agency Information Collection Activities; Proposals, Chemical Risk Management, 32917 Submissions, and Approvals, 32908–32911, 32913– 32915 Centers for Medicare & Medicaid Services Application: NOTICES Pacific Gas and Electric Co., 32906–32907 Agency Information Collection Activities: Proposed Union Falls Hydropower LP, Erie Boulevard Hydropower Collection; Comment Request; Correction, 32924 LP, 32902–32903 Agency Information Collection Activities; Proposals, Combined Filings, 32900–32901, 32903–32908, 32911– Submissions, and Approvals, 32924–32927 32913 Complaint: Coast Guard City of Lubbock, Acting by and Through Its Municipally PROPOSED RULES Owned Electric Utility Lubbock Power and Light v. Special Local Regulations: Public Service Company of Colorado, Southwestern Festival of Sail Duluth 2019, Lake Superior, Duluth, MN, Public Service Co., 32901 32849–32851 Filing: Spire Storage West, LLC, 32915–32916 Commerce Department Initial Market-Based Rate Filings Including Requests for See International Trade Administration Blanket Section 204 Authorizations: See National Oceanic and Atmospheric Administration Renewable Energy Asset Management Group, LLC, NOTICES Request for Information: 32899–32900 Report on the State of Counterfeit and Pirated Goods Meetings: Trafficking and Recommendations, 32861–32863 ISO New England Inc.; Constellation Mystic Power, LLC, 32903–32904 Commodity Futures Trading Commission Petition for Declaratory Order: NOTICES SFPP, LP, 32901–32902 Requests for Nominations: Climate-Related Market Risk Subcommittee Under the Federal Highway Administration Market Risk Advisory Committee, 32888–32889 NOTICES Final Federal Agency Actions: Education Department California; Proposed Highway, 32970–32971 NOTICES California; Proposed Highway Improvement, 32969– Agency Information Collection Activities; Proposals, 32970 Submissions, and Approvals: Foreign Schools Eligibility Criteria Apply To Participate in Title IV HEA Programs, 32895 Federal Reserve System Privacy Act; Systems of Records, 32889–32895 NOTICES Privacy Act; Systems of Records: Formations of, Acquisitions by, and Mergers of Savings and Migrant Student Information Exchange, 32895–32899 Loan Holding Companies, 32916 VerDate Sep<11>2014 19:34 Jul 09, 2019 Jkt 247001 PO 00000 Frm 00001 Fmt 4748 Sfmt 4748 E:\FR\FM\10JYCN.SGM 10JYCN jspears on DSK30JT082PROD with CONTENTS IV Federal Register / Vol. 84, No. 132 / Wednesday, July 10, 2019 / Contents Fish and Wildlife Service Taxpayer Advocacy Panel’s Special Projects Committee, NOTICES 32973 Marine Mammals; Incidental Take During Specified Taxpayer Advocacy Panel’s Toll-Free Phone Line Project Activities: Committee, 32972 Proposed Incidental Harassment Authorizations for Taxpayer Advocacy Panel’s Tax Forms and Publications Northern Sea Otters in Southeast Alaska, 32932– Project Committee, 32972 32945 International Trade Administration Food and Drug Administration NOTICES PROPOSED RULES Antidumping or Countervailing Duty Investigations, Orders, Guidance: or Reviews: The Use of an Alternate Name for
Recommended publications
  • APPENDIX a Scoping Letter, NOP, and NOP Comments
    APPENDIX A Scoping Letter, NOP, and NOP Comments THE CITY OF SAN DIEGO PLANNING DEPARTMENT Date of Notice: November 24, 2014 PUBLIC NOTICE OF THE PREPARATION OF A PROGRAM ENVIRONMENTAL IMPACT REPORT AND A SCOPING MEETING INTERNAL ORDER No. 21003411 PUBLIC NOTICE: The City of San Diego as the Lead Agency has determined that the project described below will require the preparation of a Program Environmental Impact Report (PEIR) in compliance with the California Environmental Quality Act (CEQA). This Notice of Preparation of a PEIR and Scoping Meeting was publicly noticed and distributed on November 24, 2014. This notice was published in the SAN DIEGO DAILY TRANSCRIPT and placed on the City of San Diego website at: http://www.sandiego.gov/city-clerk/officialdocs/notices/index.shtml SCOPING MEETING: Two public scoping meetings will be held by the City of San Diego's Planning Department one on Tuesday, December 9, 2014 from 5:30 p.m. to 7:30 PM at the South Bay Recreation Center located at 1885 Coronado Avenue, San Diego CA 92154, and one on Thursday, December 11, 2014 from 6:00 PM to 8:00 PM at the Public Utilities Department Metropolitan Operations Complex located at 9192 Topaz Way, San Diego CA 92123. Please note that depending on the number of attendees, the meeting could end earlier than the end times noted above. Verbal and written comments regarding the scope and alternatives of the proposed EIR will be accepted at the meeting. Please send in written/mail-in comments may also be sent to the following address: Myra Herrmann, Environmental Planner, City of San Diego Development Services Center, 1222 First Avenue, MS 501, San Diego, CA 92101 or e-mail your comments to [email protected] with the Project Name and Number in the subject line Number in the subject line within 30 days of the receipt of this notice/date of the Public Notice above.
    [Show full text]
  • Triptans Step Therapy/Quantity Limit Criteria
    Triptans Step Therapy/Quantity Limit Criteria Program may be implemented with the following options 1) step therapy 2) quantity limits or 3) step therapy with quantity limits For Blue Cross and Blue Shield of Illinois Option 1 (step therapy only) will apply. Brand Generic Dosage Form Amerge® naratriptan tablets Axert® almotriptan tablets Frova® frovatriptan tablets Imitrex® sumatriptan injection*, nasal spray, tablets* Maxalt® rizatriptan tablets Maxalt-MLT® rizatriptan tablets Relpax® eletriptan tablets Treximet™ sumatriptan and naproxen tablets Zomig® zolmitriptan tablets, nasal spray Zomig-ZMT® zolmitriptan tablets * generic available and included as target agent in quantity limit edit FDA APPROVED INDICATIONS1-7 The following information is taken from individual drug prescribing information and is provided here as background information only. Not all FDA-approved indications may be considered medically necessary. All criteria are found in the section “Prior Authorization Criteria for Approval.” Amerge® Tablets1, Axert® Tablets2, Frova® Tablets3,Imitrex® injection4, Imitrex Nasal Spray5, Imitrex Tablets6, Maxalt® Tablets7, Maxalt-MLT® Tablets7, Relpax® Tablets8, Treximet™ Tablets9, Zomig® Tablets10, Zomig-ZMT® Tablets10, and Zomig® Nasal Spray11 Amerge (naratriptan), Axert (almotriptan), Frova (frovatriptan), Imitrex (sumatriptan), Maxalt (rizatriptan), Maxalt-MLT (rizatriptan orally disintegrating), Relpax (eletriptan), Treximet (sumatriptan/naproxen), Zomig (zolmitriptan), and Zomig-ZMT (zolmitriptan orally disintegrating) tablets, and Imitrex (sumatriptan) and Zomig (zolmitriptan) nasal spray are all indicated for the acute treatment of migraine attacks with or without aura in adults. They are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Safety and effectiveness of all of these products have not been established for cluster headache, which is present in an older, predominantly male population.
    [Show full text]
  • Medication Guide 2012
    DeKalb County D.U.I. Court Supervised Treatment Program MEDICATION GUIDE Medication Guide 2012 DeKalb County State Court Decatur, Georgia xxi ********** WELCOME TO THE DEKALB COUNTY D.U.I. COURT SUPERVISED TREATMENT PROGRAM. This 2012 Medication Guide was developed as a collaborative effort by Becky Pirouz, Pharm.D., Director of Pharmacy, Peachford Hospital, and by Lois Michalove, Treatment Coordinator for the DeKalb County D.U.I. Court Supervised Treatment Program, both of whom have extensive experience in addiction recovery and treatment. ********** The following information is intended to assist you in making decisions about medications. This may include those medications that you are prescribed and/or your selection of over-the-counter (OTC) products. Unintended exposure may compromise your treatment program. This is not an exhaustive list, but contains some of the medications that are most commonly used. If in doubt, always consult the Treatment Coordinator. Please inform your physician, dentist, pharmacist and other health care professionals that you are in a recovery program. WE ARE A ZERO-TOLERANCE PROGRAM! DO NOT COMPROMISE YOUR RECOVERY BY MAKING HIGH-RISK CHOICES! xxii - Section 1 – Drugs To Avoid The following drugs must not be used at any time. They are well known to be abused and even small amounts may result in relapse and are contraindicated in your treatment program. However, extenuating circumstances may occur which necessitates the short- term limited use of some of the drugs on this list in consultation with your physician, the Judge and the Treatment Coordinator. This decision should be made prior to your ingestion of any of the Drugs to Avoid.
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • NEW PATIENT QUESTIONNAIRE - Page 1
    __________________________ Clinical Neurosciences Center NEW PATIENT QUESTIONNAIRE - Page 1 Provider you will be seeing: Date of Appointment: Patient Name: Date of Birth: Age: Home Address / City / State / Zip: Home Phone: Work Phone: Cell: Email: Emergency Contact: Phone: PHYSICIAN INFORMATION - What is the name of your PRIMARY CARE PROVIDER: Address / City / State: Phone: What is the name your REFERRING PROVIDER (if different from above): Address / City / State: Phone: HEADACHE SPECIFIC QUESTIONS - What is your biggest concern about your headaches: Do you have sick / severe headaches: YES NO Date sick / severe headache started: How many sick / severe headaches have you had in your life: 0-2 3-10 11-20 21-50 51-100 >100 Frequency of sick / severe headaches (per month and per year): AGE MONTH YEAR DESCRIBE As a child less than 12 years As an adolescent 13-18 years As a young adult 19-30 years As an adult over 30 years Were you adopted: YES NO Does anyone in the family have headaches (migraine, sick, sinus, tension, cluster, other): RELATION YES NO DESCRIBE RELATION YES NO DESCRIBE Mother Father M. Gma P. Gma M. Gpa P. Gpa M. Aunts P. Aunts M. Uncles P. Uncles Sisters Brothers Daughters Sons Were you ever carsick as a child: YES NO NEW PATIENT QUESTIONNAIRE - Page 2 SOME PEOPLE HAVE MORE THAN ONE TYPE OF HEADACHE - How many days have you had a headache in the last: month: days 3 months: days 6 months: days Visits to the ER in the last 12 months: visits Days missed at work or school in the last month: days On a scale of 1-10, on average,
    [Show full text]
  • NARATRIPTAN 2.5 MG FILM-COATED TABLETS [Naratriptan (As Naratriptan Hydrochloride)] Read All of This Leaflet Carefully Before You Start Taking This Medicine
    PACKAGE LEAFLET: INFORMATION FOR THE USER NARATRIPTAN 2.5 MG FILM-COATED TABLETS [Naratriptan (as naratriptan hydrochloride)] Read all of this leaflet carefully before you start taking this medicine. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist (chemist). • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their CODE symptoms are the same as yours. CODE • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. In this leaflet: 1. What Naratriptan is and what it is used for 2. Before you take Naratriptan 3. How to take Naratriptan 4. Possible side effects 5. How to store Naratriptan 6. Further information Zentiva 1. What Naratriptan is and what it is used for Brand: PIL NARATRIPTAN 2.5MG 6 AND 12 FCT 156X348MM Naratriptan contains naratriptan (hydrochloride), which belongs to a group of medicines called triptans (also Category: LEAFLET known as 5-HT1 receptor agonists). Argus Code: 000 Naratriptan tablets are used to treat migraine with or without aura. Spec No: 00000 Migraine symptoms may be caused by the temporary widening of blood vessels in the head. Naratriptan tablets Supersedes: 00000 are believed to reduce the widening of these blood vessels. This in turn helps to take away the headache and Core Spec No: 00000 relieve other symptoms of a migraine attack, such as feeling or being sick (nausea or vomiting) and sensitivity to light and sound.
    [Show full text]
  • UCSF UC San Francisco Electronic Theses and Dissertations
    UCSF UC San Francisco Electronic Theses and Dissertations Title Deep phenotypic profiling of neuroactive drugs in larval zebrafish Permalink https://escholarship.org/uc/item/3vk1d0gr Author Gendelev, Leo Publication Date 2019 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California Deep phenotypic profiling of neuro-active drugs in larval Zebrafish by Lev Gendelev DISSERTATION Submitted in partial satisfaction of the requirements for degree of DOCTOR OF PHILOSOPHY in Biophysics in the GRADUATE DIVISION of the UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Approved: ______________________________________________________________________________Michael Keiser Chair ______________________________________________________________________________DAVID KOKEL ______________________________________________________________________________Jim Wells ______________________________________________________________________________ ______________________________________________________________________________ Committee Members Copyright 2019 by Lev (Leo) Gendelev ii In Loving Memory of My Mother, Lucy Gendelev iii Acknowledgements First of all, I thank my advisor, Michael Keiser, for his unwavering support through the most difficult of times. I will above all else reminisce over our brainstorming sessions, where my half- wrought white-board scribbles were met with enthusiasm and sometimes even developed into exciting side-projects. My PhD experience felt less like work and more like a fantastical scientific
    [Show full text]
  • Triptan Therapy for Acute Migraine
    Triptan Therapy for Acute Migraine Headache John Farr Rothrock, MD University of Alabama at Birmingham, Birmingham, AL Deborah I. Friedman, MD, MPH University of Texas Southwestern, Dallas, TX The “triptans” are 5HT-1B/1D receptor agonists that were developed to treat acute migraine and acute cluster headache. Sumatriptan, the original triptan preparation, has been in general use since 1993, so there has been considerable experience with triptans over time. There are currently seven oral triptans on the market in the United States: sumatriptan (Imitrex™), naratriptan (Amerge™), zolmitriptan (Zomig™), rizatriptan (Maxalt™), almotriptan (Axert™), frovatriptan (Frova™), and eletriptan (Relpax™); brand names may differ by country. There is also a combination preparation of oral sumatriptan/naproxen (Treximet™). Two triptans (sumatriptan, zolmitriptan) are marketed as nasal sprays, and sumatriptan is available for subcutaneous injection, including a needle-free subcutaneous delivery system (Sumavel™). Sumatriptan suppositories are marketed in Europe but not in North America. Zolmitriptan and rizatriptan are sold in an oral disintegrating tablet or “melt” formulation as well as in tablet form; while the “melt” formulations may be more convenient (no liquid is required to propel them into the stomach), they are absorbed similarly to regular tablets and there is no evidence to suggest that they work faster than the tablet formulations. Some patients with migraine-associated nausea prefer the disintegrating tablets while others cannot tolerate their taste. Although all of the triptans initially were investigated for the treatment of migraine headache of moderate to severe intensity and were superior to placebo in those pivotal trials, they appear to be more consistently effective when used to treat migraine earlier in the attack, when the headache is still mild to moderate.
    [Show full text]
  • Engineered Cells for Production of Indole-Derivatives
    Downloaded from orbit.dtu.dk on: Oct 05, 2021 Engineered cells for production of indole-derivatives Kell, Douglas; Yang, Lei; Malla, Sailesh Publication date: 2020 Document Version Publisher's PDF, also known as Version of record Link back to DTU Orbit Citation (APA): Kell, D., Yang, L., & Malla, S. (2020). Engineered cells for production of indole-derivatives. (Patent No. WO2020187739). General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. Users may download and print one copy of any publication from the public portal for the purpose of private study or research. You may not further distribute the material or use it for any profit-making activity or commercial gain You may freely distribute the URL identifying the publication in the public portal If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. ) ( 2 (51) International Patent Classification: C07K 14/715 (2006.01) (21) International Application Number: PCT/EP2020/056828 (22) International Filing Date: 13 March 2020 (13.03.2020) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 19163 184.5 15 March 2019 (15.03.2019) EP (71) Applicant: DANMARKS TEKNISKE UNIVERSITET [DK/DK]; Anker Engelunds Vej 101 A, 2800 Kgs. Lyngby (DK). (72) Inventors: KELL, Douglas, Bruce; Chirk Manor, Trevor Rd, Chirk, Wrexham LL14 5HD (GB).
    [Show full text]
  • Recreational Use, Analysis and Toxicity of Tryptamines
    Send Orders for Reprints to [email protected] 26 Current Neuropharmacology, 2015, 13, 26-46 Recreational Use, Analysis and Toxicity of Tryptamines Roberta Tittarelli1, Giulio Mannocchi1, Flaminia Pantano1 and Francesco Saverio Romolo1,2,* 1Legal Medicine Section, Department of Anatomical, Histological, Forensic Medicine and Orthopedic Sciences, “Sapienza” University of Rome, Viale Regina Elena, 336, 00161 Rome, Italy; 2Institut de Police Scientifique, Université de Lausanne, Batochime, 1015 Lausanne, Switzerland Abstract: The definition New psychoactive substances (NPS) refers to emerging drugs whose chemical structures are similar to other psychoactive compounds but not identical, representing a “legal” alternative to internationally controlled drugs. There are many categories of NPS, such as synthetic cannabinoids, synthetic cathinones, phenylethylamines, piperazines, ketamine derivatives and tryptamines. Tryptamines are naturally occurring compounds, which can derive from the amino acid tryptophan by several biosynthetic pathways: their structure is a combination of a benzene ring Roberta Tittarelli and a pyrrole ring, with the addition of a 2-carbon side chain. Tryptamines include serotonin and melatonin as well as other compounds known for their hallucinogenic properties, such as psilocybin in ‘Magic mushrooms’ and dimethyltryptamine (DMT) in Ayahuasca brews. Aim: To review the scientific literature regarding tryptamines and their derivatives, providing a summary of all the available information about the structure of these compounds, their effects in relationship with the routes of administration, their pharmacology and toxicity, including articles reporting cases of death related to intake of these substances. Methods: A comprehensive review of the published scientific literature was performed, using also non peer-reviewed information sources, such as books, government publications and drug user web fora.
    [Show full text]
  • Triptans in the Treatment of Migraine in Adults
    The role of triptans in the treatment of migraine in adults 28 Paracetamol or a non-steroidal anti-inflammatory drug (NSAID) can be used first-line for pain relief in acute migraine. A triptan can then be trialled if this was not successful. Combination treatment with a triptan and paracetamol or NSAID may be required for some patients. Most triptans are similarly effective, so choice is usually based on formulation, e.g. a non-oral preparation may be more suitable for patients with nausea or vomiting. To avoid medication overuse headache, triptan use should not exceed ten or more days per month. Migraine is a condition characterised by attacks of moderate A stepwise approach to managing migraine: to severe, throbbing headache, which is usually unilateral. This triptans are appropriate at step two is often associated with other symptoms, including nausea, vomiting, photophobia or phonophobia. Approximately one- There are a number of treatment guidelines for acute migraine, third of patients with migraines also experience a preceding all of which differ slightly in their recommended approach (see aura. Worldwide, approximately one in every seven people the NICE and BASH guidelines).3, 4 Most algorithms, however, are affected by migraines, which are often associated with recommend stepwise treatment, with triptans usually tried significant personal and socioeconomic impact.1 In the Global after paracetamol and NSAIDs. Burden of Disease Survey 2010, migraine was ranked as the third most prevalent disorder and the seventh-highest specific A reasonable approach is: 2 cause of disability. Step 1: Over-the-counter analgesics (paracetamol, NSAIDs) Step 2: Triptan For information on diagnosing migraine, see: Step 3: Combination treatment with a triptan and an NSAID National Institute for Health and Care Excellence (NICE) +/- anti-emetic (prochlorperazine, metoclopramide) at Guideline: Headaches.
    [Show full text]
  • Cyclisation of Indoles by Using Orthophosphoric Acid in Sumatriptan and Rizatriptan
    Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2013, 5(8):107-109 ISSN : 0975-7384 Research Article CODEN(USA) : JCPRC5 Cyclisation of indoles by using orthophosphoric acid in sumatriptan and rizatriptan K. Sudarshan Rao, K. Nageswara Rao, Bhausaheb Chavan, P. Muralikrishna and A. Jayashree Centre for Chemical Sciences and Technology, IST, Jawaharlal Nehru Technological University, Kukatpally, Hyderabad, Andhra Pradesh, India _____________________________________________________________________________________________ ABSTRACT A simple and Novel improved process for the preparation of pure Sumatriptan and Rizatriptan, the cyclisation of indole ring by the using of ortho phosphoric acid. The present work describes the detection, origin, synthesis, characterization and providing a commercial method to synthesize Sumatriptan and Rizatriptan. The procedure developed has several advantages such as mild reaction conditions, convenient operations and easily obtained materials. The synthetic method is suitable for industrial manufacture. Keywords: Cyclisation, Sumatriptan, Rizatriptan, ortho phosphoric acid, _____________________________________________________________________________________________ INTRODUCTION Triptans are a family of tryptamine-based drugs used as abortive medication in the treatment of migraines and cluster headaches. They were first introduced in the 1990s. While effective at treating individual headaches, they do not provide preventative treatment and are not considered a cure. The first triptan (i.e., tryptamine derivative) to be marketed for the acute treatment of migraine, sumatriptan, has been so successful that a number of second generation triptans are now marketed or in the late stages of clinical development 1,2 . The triptans represent a breakthrough in acute migraine treatment, being far more selective for 5-HT1B-1D receptors than their relatively nonselective predecessor’s ergotamine and dihydroergotamine (DHE) 3,4 .
    [Show full text]